DMAC - DiaMedica Therapeutics - Stock Forecast

Healthcare - Sector
Coverage Stock analysts Price Targets & Ratings Chart Insider Trading

DMAC is currently covered by 2 analysts with an average price target of $17.28. This is a potential upside of $10.4 (151.16%) from yesterday's end of day stock price of $6.88.

DiaMedica Therapeutics's activity chart (see below) currently has 25 price targets and 31 ratings on display. The stock rating distribution of DMAC is 100% BUY.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 17.86% with an average time for these price targets to be met of 205.43 days.

Highest price target for DMAC is $14, Lowest price target is $12, average price target is $13.

Most recent stock forecast was given by MATTHEW CAUFIELD from HC WAINWRIGHT on 14-Aug-2025. First documented stock forecast 02-Jan-2019.

Currently out of the existing stock ratings of DMAC, 6 are a BUY (100%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Buy

$12

$5.12 (74.42%)

$12

2 months 12 days ago
(14-Aug-2025)

2/6 (33.33%)

$5.97 (99.00%)

315

Buy

$14

$7.12 (103.49%)

3 months 9 days ago
(17-Jul-2025)

0/2 (0%)

$9.82 (234.93%)

Buy

$6

$-0.88 (-12.79%)

$6

1 years 2 months 11 days ago
(15-Aug-2024)

3/4 (75%)

$2.4 (66.67%)

403

Buy

$8

$1.12 (16.28%)

$8

1 years 6 months 3 days ago
(23-Apr-2024)

1/6 (16.67%)

$5.55 (226.53%)

720

Buy

4 years 1 months ago
(26-Sep-2021)

0/1 (0%)

$27.58 (264.68%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

What is DMAC (DiaMedica Therapeutics) average time for price targets to be met?

On average it took 205.43 days on average for the stock forecasts to be realized with a an average price target met ratio 17.86

Which analyst has the current highest performing score on DMAC (DiaMedica Therapeutics) with a proven track record?

FRANCOIS BRISEBOIS

Which analyst has the current lower performing score on DMAC (DiaMedica Therapeutics) with a proven track record?

JASON MCCARTHY

Which analyst has the most public recommendations on DMAC (DiaMedica Therapeutics)?

Francois Brisebois works at OPPENHEIMER and has 3 price targets and 2 ratings on DMAC

Which analyst is the currently most bullish on DMAC (DiaMedica Therapeutics)?

Etzer Darout with highest potential upside - $18.12

Which analyst is the currently most reserved on DMAC (DiaMedica Therapeutics)?

Francois Brisebois with lowest potential downside - -$0.88

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?